Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Total Liabilities (2016 - 2025)

IGC Pharma (IGC) has disclosed Total Liabilities for 15 consecutive years, with $1.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Liabilities fell 44.82% to $1.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.7 million, a 44.82% decrease, with the full-year FY2025 number at $2.4 million, down 6.35% from a year prior.
  • Total Liabilities was $1.7 million for Q3 2025 at IGC Pharma, down from $1.9 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $3.1 million in Q1 2021 to a low of $1.7 million in Q3 2025.
  • A 5-year average of $2.4 million and a median of $2.4 million in 2025 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: surged 32.75% in 2023, then tumbled 44.82% in 2025.
  • IGC Pharma's Total Liabilities stood at $1.8 million in 2021, then fell by 3.31% to $1.8 million in 2022, then increased by 25.84% to $2.2 million in 2023, then grew by 27.79% to $2.8 million in 2024, then tumbled by 41.43% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Total Liabilities are $1.7 million (Q3 2025), $1.9 million (Q2 2025), and $2.4 million (Q1 2025).